These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32683457)

  • 61. Midostaurin Gets FDA Nod for AML.
    Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071627
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
    Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
    J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Novel therapies for AML: a round-up for clinicians.
    Swaminathan M; Wang ES
    Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1389-1400. PubMed ID: 33412978
    [No Abstract]   [Full Text] [Related]  

  • 66. New Treatment Options for Acute Myeloid Leukemia in 2019.
    Cerrano M; Itzykson R
    Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An evaluation of glasdegib for the treatment of acute myelogenous leukemia.
    Thomas X; Heiblig M
    Expert Opin Pharmacother; 2020 Apr; 21(5):523-530. PubMed ID: 32027196
    [No Abstract]   [Full Text] [Related]  

  • 68. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Management of Acute Myeloid Leukemia (AML) in Older Patients.
    Abdallah M; Xie Z; Ready A; Manogna D; Mendler JH; Loh KP
    Curr Oncol Rep; 2020 Jul; 22(10):103. PubMed ID: 32725515
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Progress in acute myeloid leukaemia: small molecular inhibitors with small benefits.
    Hilal T
    Ecancermedicalscience; 2020; 14():1015. PubMed ID: 32256698
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
    Wang ES
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Is the overall survival for older adults with AML finally improving?
    Lancet JE
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association.
    Stemler J; de Jonge N; Skoetz N; Sinkó J; Brüggemann RJ; Busca A; Ben-Ami R; Ráčil Z; Piechotta V; Lewis R; Cornely OA
    Lancet Haematol; 2022 May; 9(5):e361-e373. PubMed ID: 35483397
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quizartinib (AC220): a promising option for acute myeloid leukemia.
    Zhou F; Ge Z; Chen B
    Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.
    Venugopal S; Xie Z; Zeidan AM
    Expert Rev Hematol; 2023 Feb; 16(2):109-119. PubMed ID: 36718500
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia.
    Kang D; Ludwig E; Jaworowicz D; Huang H; Fiedler-Kelly J; Cortes J; Ganguly S; Khaled S; Krämer A; Levis M; Martinelli G; Perl A; Russell N; Abutarif M; Choi Y; Yin O
    Cancer Chemother Pharmacol; 2021 Apr; 87(4):513-523. PubMed ID: 33415416
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
    Click ZR; Seddon AN; Bae YR; Fisher JD; Ogunniyi A
    Pharmacotherapy; 2018 Nov; 38(11):1143-1154. PubMed ID: 30220082
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
    Jones AK; Freise KJ; Agarwal SK; Humerickhouse RA; Wong SL; Salem AH
    AAPS J; 2016 Sep; 18(5):1192-1202. PubMed ID: 27233802
    [TBL] [Abstract][Full Text] [Related]  

  • 79. First Approved Kinase Inhibitor for AML.
    Rasko JEJ; Hughes TP
    Cell; 2017 Nov; 171(5):981. PubMed ID: 29149610
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Midostaurin in FLT3-mutated acute myeloid leukaemia.
    Das M
    Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.